Product: Semaglutide Classification: Class II Reason for recall: CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution Product description: Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04; e) 100g, NDC 84385-106-05Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China. Recalling firm: Harbin Jixianglong Biotech Co., Ltd. Product type: Drugs
FDA MedWatch published a clinical safety alert in Pharmacology on 11 Mar 2026.
The item focuses on Semaglutide: Class II recall update.
Review the original article for the full source wording and details.